Differential properties of the optical-isomers of pranidipine, a 1,4- dihydropyridine calcium channel modulator

Fundamental and Clinical Pharmacology

Volumn 13, Issue 6, 1999, Pages 650-655

  Hirano, Takahiro ^a   Mori, Toyoki ^a   Kido, Masaru ^a   Toide, Kiyotaka ^a   Ohura, Makoto ^a   Fujiki, Hiroyuki ^a   Orito, Kensuke ^a   Yoshida, Kenji ^a   Ikezono, Katsumi ^a   Sumida, Takumi ^a   Nakayama, Natsuki ^a   Yabuuchi, Youichi ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anaesthetized rat; Calcium channel blocking action; Isolated aorta; Optical isomers; Pranidipine; Spontaneously hypertensive rats; Structure activity relationship

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 1,4 DIHYDROPYRIDINE; CALCIUM; CALCIUM CHANNEL AFFECTING AGENT; CALCIUM CHANNEL BLOCKING AGENT; POTASSIUM CHLORIDE; PRANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA MEDIA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG STRUCTURE; ISOMER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0033452050     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1999.tb00376.x     Document Type: Article

References (26)

1. [1] Nakayama N., Ikezono K., Mori T., Yamashita S., Nakayama S., Tanaka Y. et al., Antihypertensive activity of OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist in rats, J. Cardiovasc. Pharmacol. 15 (1990) 836-844.
2. [2] Nakayama N., Ikezono K., Fujio N., Sasabe H., Kitaura K., Tamada S., Shirafuji T., Yabuuchi Y., OPC-13340, a new potent long-acting dihydropyridine calcium antagonist, Cardiovasc. Drug. Rev. 9 (1991) 147-157.
3. [3] Nakayama N., Ikezono K., Ohura M., Yabuuchi Y., Effects of the new long-acting dihydropyridine calcium antagonist pranidipine on the endothelium-dependent relaxation in isolated rat aorta in vitro, Arzneim.-Forsch., Drug Res. 43 (1993) 1266-1270.
4. [4] Miyakoda G., Nakayama N., Matsui K., Yabuuchi Y., Mechanisms of the potent long-lasting antihypertensive action of the new calcium channel blocker pranidipine. Evidence for strong affinity to the calcium channels or membrane, Arzneim.-Forsch., Drug Res. 45 (1995) 471-475.
5. 2+ channel antagonist, in rats: comparison with nifedipine and amIodipine, Eur. J. Pharmacol. 324 (1997) 201-204.
6. [6] Mori T., Nakayama N., Ohura M., Ikezono K., Kinoshita S., Kamata M. et al., Cardiovascular effects of OPC-13340, a potent, long-acting 1,4-dihydropyridine calcium channel blocker, in dogs, Arch. Int. Pharmacodyn. Ther. 321 (1993) 41-56.
7. 2+ channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta, Mol. Cell. Biochem. 178 (1998) 335-343.
8. [8] Broadhurst P., Brigden G., Hittel N., Lahiri A., Raftery E.B., Prolonged hypotensive effect of OPC-13340: a new, once-daily calcium channel blocking drug, Eur. Heart. J. 12 (1991) 434-438.
9. [9] Tominaga M., Tsuchihashi T., Kinoshita H., Kobayashi K., Ohya Y., Abe I., Takata Y., Fujishima M., Ambulatory blood pressure monitoring in elderly hypertensives treated with the new calcium antagonist, pranidipine (OPC-13340), Int. J. Clin. Pharmacol. Ther. 33 (1995) 277-280.
10. [10] Rosenthal J., Hittel N., Stumpe K.O., Pranidipine, a novel calcium antagonist, once daily, for the treatment of hypertension: a multicenter, double-blind, placebo-controlled dose-finding study, Cardiovasc. Drugs. Ther. 10 (1996) 59-66.
11. [11] Nishinaka Y., Yokota M., Watanabe M., Sobue T., Iwase M., Ukai M., Ando A., Nagata K., Saito H., Haemodynamic effects of the calcium channel blocker pranidipine on exercise-induced angina, Int. J. Clin. Pharmacol. Ther. 32 (1994) 542-549.
12. [12] Goldmann S., Stoltefuss J., 1,4-Dihydropyridines: effects of chirality and conformation on the calcium antagonist and calcium agonist activities, Angew. Chem. Int. Ed. Engl. 30 (1991) 1559-1578.
13. [13] Rampe D., Kane J.M., Activators of voltage-dependent L-type calcium channels, Drug. Dev. Res. 33 (1994) 344-363.
14. [14] Franckowiak G., Bechem M., Schramm M., Thomas G., The optical isomers of the 1,4-dihydropyridine Bay K 8644 show opposite effects on Ca channels, Eur. J. Pharmacol. 114 (1985) 223-226.
15. [15] Williams J.S., Grupp I.L., Grupp G., Vaghy P.L., Dumont L., Schwartz A., Profile of the oppositely acting enantiomers of the dihydropyridine 202-791 in cardiac preparations: receptor binding, electrophysiological and pharmacological studies, Biochem. Biophys. Res. Commun. 131 (1985) 13-21.
16. [16] Gjorstrup P., Harding H., Isaksson R., Westerlund C., The enantiomers of the dihydropyridine derivative H 160 51 show opposite effects of stimulation and inhibition, Eur. J. Pharmacol. 122 (1986) 357-361.
17. [17] Schwarz A., Recent new studies on localization of the calcium antagonist binding receptor sites on the calcium channel, High Blood Pressure 3 (1994) 291-294.
18. [18] Hockerman G.H., Peterson B.Z., Johnson B.D., Catterall W.A., Molecular determinations of drug binding and action on L-type calcium channels, Annu. Rev. Pharmacol. Toxicol. 37 (1997) 361-396.
19. 2+ channel block and inactivation: common molecular determinants, Trends Pharmacol. Sci. 19 (1998) 439-443.
20. 2+ channels, Trends Pharmacol. Sci. 19 (1998) 108-115.
21. [21] Arunlakshana O., Schild H.O., Some quantative uses of drug antagonist, Br. J. Chem. Pharmacol. 14 (1959) 48-58.
22. [22] Van Rossum J.M., Cumulative dose-response curves, Arch. Inst. Pharmacodyn. Ther. 143 (1963) 299-330.
23. [23] Stewart J.J.P., A semiempirical molecular orbital program, J. Comput.-Aided Mol. Des. 4 (1990) 1-45.
24. [24] Hoffman H.J., Cimiraglia R., Conformation of 1,4-dihydropyridine - planar or boat-like?, FEBS Lett. 241 (1988) 38-40.
25. [25] Nakaya H., Hattori Y., Tohse N., Kanno M., Voltage-dependent effects of YC-170, a dihydropyridine calcium channel modulator, in cardiovascular tissues, Naunyn-Schmiedeberg's Arch. Pharmacol. 333 (1986) 421-430.
26. [26] Ohura M., Orito K., Miyakoda G., Mori T., The selective vascular and negative chronotropic effects versus negative inotropic effects of pranidipine, a new 1,4-dihydropyridine calcium channel blocker, in isolated rat preparations, Jpn. J. Pharmacol. 73 (Supplement I) (1997) 70 (Abstract).